Compare Abrdn Physical Platinum Shares ETF (PPLT) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abrdn Physical Platinum Shares ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? Abrdn Physical Platinum Shares ETF trades at $14.56 (market cap $2.00B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 3.7× Abrdn Physical Platinum Shares ETF's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Abrdn Physical Platinum Shares ETF for 43 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PPLT | SYRE | |
|---|---|---|
Market Cap | $2.00B | $7.35B |
Volume | 1,178,871 | 1,624,631 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $25.23 | $108.92 |
52-Week Low | $13.73 | $22.18 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | — | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLT, the abrdn Physical Platinum Shares ETF, trades at $15.05, down 1.44% with a bearish technical outlook. Moving averages signal strong selling pressure while oscillators remain neutral. Recent news highlights platinum's underperformance in the precious metals rally, with some analysts viewing it as a potential catch-up trade opportunity despite current bearish technicals.
The ETF faces headwinds from platinum's term structure in contango, suggesting adequate supply. Historical seasonality offers some counterpoint to the bearish outlook. Investment opportunity exists if platinum catches up to gold and silver's recent rally, though supply dynamics and technical weakness present near-term risks.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
